Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Targeted therapy and disease monitoring in CNTRL-FGFR1-driven leukaemia.

Brown LM, Bartolo RC, Davidson NM, Schmidt B, Brooks I, Challis J, Petrovic V, Khuong-Quang DA, Mechinaud F, Khaw SL, Majewski IJ, Oshlack A, Ekert PG.

Pediatr Blood Cancer. 2019 Jun 28:e27897. doi: 10.1002/pbc.27897. [Epub ahead of print]

PMID:
31250523
2.

Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.

Meyer C, Lopes BA, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, Sutton R, Venn NC, Oh SH, Tsaur G, Escherich G, Feuchtinger T, Kosasih HJ, Khaw SL, Ekert PG, Pombo-de-Oliveira MS, Bidet A, Djahanschiri B, Ebersberger I, Zaliova M, Zuna J, Zermanova Z, Juvonen V, Grümayer RP, Fazio G, Cazzaniga G, Larghero P, Emerenciano M, Marschalek R.

Leukemia. 2019 Mar 21. doi: 10.1038/s41375-019-0451-7. [Epub ahead of print] No abstract available.

PMID:
30899083
3.

Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N.

Nat Genet. 2019 Jan;51(1):196. doi: 10.1038/s41588-018-0304-8.

PMID:
30429576
4.

Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N.

Nat Genet. 2018 Dec;50(12):1650-1657. doi: 10.1038/s41588-018-0251-4. Epub 2018 Oct 29. Erratum in: Nat Genet. 2018 Nov 14;:.

PMID:
30374066
5.

Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.

Tsoli M, Wadham C, Pinese M, Failes T, Joshi S, Mould E, Yin JX, Gayevskiy V, Kumar A, Kaplan W, Ekert PG, Saletta F, Franshaw L, Liu J, Gifford A, Weber MA, Rodriguez M, Cohn RJ, Arndt G, Tyrrell V, Haber M, Trahair T, Marshall GM, McDonald K, Cowley MJ, Ziegler DS.

Cancer Biol Ther. 2018;19(12):1078-1087. doi: 10.1080/15384047.2018.1491498. Epub 2018 Oct 9.

6.

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

Ziegler DS, Wong M, Mayoh C, Kumar A, Tsoli M, Mould E, Tyrrell V, Khuong-Quang DA, Pinese M, Gayevskiy V, Cohn RJ, Lau LMS, Reynolds M, Cox MC, Gifford A, Rodriguez M, Cowley MJ, Ekert PG, Marshall GM, Haber M.

Br J Cancer. 2018 Sep;119(6):693-696. doi: 10.1038/s41416-018-0251-2. Epub 2018 Sep 17.

PMID:
30220707
7.

Clinker: visualizing fusion genes detected in RNA-seq data.

Schmidt BM, Davidson NM, Hawkins ADK, Bartolo R, Majewski IJ, Ekert PG, Oshlack A.

Gigascience. 2018 Jul 1;7(7). doi: 10.1093/gigascience/giy079.

8.

Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.

Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bayır H, Abhari BA, Angeli JPF, Choi SM, Meul E, Heyninck K, Declerck K, Chirumamilla CS, Lahtela-Kakkonen M, Van Camp G, Krysko DV, Ekert PG, Fulda S, De Geest BG, Conrad M, Kagan VE, Vanden Berghe W, Vandenabeele P, Vanden Berghe T.

J Clin Invest. 2018 Aug 1;128(8):3341-3355. doi: 10.1172/JCI99032. Epub 2018 Jun 25.

9.

MicroRNA-155 expression and function in AML: An evolving paradigm.

Narayan N, Bracken CP, Ekert PG.

Exp Hematol. 2018 Jun;62:1-6. doi: 10.1016/j.exphem.2018.03.007. Epub 2018 Mar 27. Review.

PMID:
29601851
10.

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Wittwer NL, Brumatti G, Marchant C, Sandow JJ, Pudney MK, Dottore M, D'Andrea RJ, Lopez AF, Ekert PG, Ramshaw HS.

Blood Adv. 2017 Jun 20;1(15):1067-1079. doi: 10.1182/bloodadvances.2016002931. eCollection 2017 Jun 27.

11.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770
12.

Dysregulation of BCL-2 family proteins by leukemia fusion genes.

Brown LM, Hanna DT, Khaw SL, Ekert PG.

J Biol Chem. 2017 Sep 1;292(35):14325-14333. doi: 10.1074/jbc.R117.799056. Epub 2017 Jul 17. Review.

13.

Role of the β Common (βc) Family of Cytokines in Health and Disease.

Hercus TR, Kan WLT, Broughton SE, Tvorogov D, Ramshaw HS, Sandow JJ, Nero TL, Dhagat U, Thompson EJ, Shing KSCT, McKenzie DR, Wilson NJ, Owczarek CM, Vairo G, Nash AD, Tergaonkar V, Hughes T, Ekert PG, Samuel MS, Bonder CS, Grimbaldeston MA, Parker MW, Lopez AF.

Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6). pii: a028514. doi: 10.1101/cshperspect.a028514. Review.

PMID:
28716883
14.

Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.

Sandow JJ, Infusini G, Holik AZ, Brumatti G, Averink TV, Ekert PG, Webb AI.

Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201700013. Epub 2017 May 15.

PMID:
28447382
15.

Genetic determinants of anthracycline cardiotoxicity - ready for the clinic?

Craig LA, Ekert PG, Conyers R, Elliott DA.

Br J Clin Pharmacol. 2017 May;83(5):1141-1142. doi: 10.1111/bcp.13195. Epub 2017 Jan 24. No abstract available.

16.

Cycloheximide Can Induce Bax/Bak Dependent Myeloid Cell Death Independently of Multiple BH3-Only Proteins.

Goodall KJ, Finch-Edmondson ML, van Vuuren J, Yeoh GC, Gentle IE, Vince JE, Ekert PG, Vaux DL, Callus BA.

PLoS One. 2016 Nov 2;11(11):e0164003. doi: 10.1371/journal.pone.0164003. eCollection 2016.

17.

A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders.

Stark Z, Tan TY, Chong B, Brett GR, Yap P, Walsh M, Yeung A, Peters H, Mordaunt D, Cowie S, Amor DJ, Savarirayan R, McGillivray G, Downie L, Ekert PG, Theda C, James PA, Yaplito-Lee J, Ryan MM, Leventer RJ, Creed E, Macciocca I, Bell KM, Oshlack A, Sadedin S, Georgeson P, Anderson C, Thorne N, Melbourne Genomics Health Alliance, Gaff C, White SM.

Genet Med. 2016 Nov;18(11):1090-1096. doi: 10.1038/gim.2016.1. Epub 2016 Mar 3.

PMID:
26938784
18.

Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia.

Narayan N, Morenos L, Phipson B, Willis SN, Brumatti G, Eggers S, Lalaoui N, Brown LM, Kosasih HJ, Bartolo RC, Zhou L, Catchpoole D, Saffery R, Oshlack A, Goodall GJ, Ekert PG.

Leukemia. 2017 Apr;31(4):808-820. doi: 10.1038/leu.2016.279. Epub 2016 Oct 14.

PMID:
27740637
19.

Letting the breaks off MYCN.

Perini G, Milazzo G, Narayan N, Ekert PG.

Cell Death Differ. 2016 Dec;23(12):1904-1905. doi: 10.1038/cdd.2016.112. Epub 2016 Oct 14. No abstract available.

20.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub 2016 Sep 12. No abstract available.

21.

The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J.

Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. Erratum in: Sci Transl Med. 2017 May 31;9(392):.

PMID:
27194727
22.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006. Erratum in: Cancer Cell. 2016 Sep 12;30(3):499-500.

23.

Autophagy and AML--food for thought.

Lalaoui N, Johnstone R, Ekert PG.

Cell Death Differ. 2016 Jan;23(1):5-6. doi: 10.1038/cdd.2015.136. Epub 2015 Oct 30. No abstract available.

24.

The molecular relationships between apoptosis, autophagy and necroptosis.

Lalaoui N, Lindqvist LM, Sandow JJ, Ekert PG.

Semin Cell Dev Biol. 2015 Mar;39:63-9. doi: 10.1016/j.semcdb.2015.02.003. Epub 2015 Feb 28. Review.

PMID:
25736836
25.

RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.

Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, Vince JE, Lawlor KE, Ninnis RL, Anderton H, Hall C, Spall SK, Phesse TJ, Abud HE, Cengia LH, Corbin J, Mifsud S, Di Rago L, Metcalf D, Ernst M, Dewson G, Roberts AW, Alexander WS, Murphy JM, Ekert PG, Masters SL, Vaux DL, Croker BA, Gerlic M, Silke J.

Cell. 2014 May 22;157(5):1175-88. doi: 10.1016/j.cell.2014.04.019. Epub 2014 May 8.

26.

Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.

Sadras T, Perugini M, Kok CH, Iarossi DG, Heatley SL, Brumatti G, Samuel MS, To LB, Lewis ID, Lopez AF, Ekert PG, Ramshaw HS, D'Andrea RJ.

J Leukoc Biol. 2014 Jul;96(1):83-91. doi: 10.1189/jlb.2AB1013-559R. Epub 2014 Mar 5.

PMID:
24598054
27.

The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts.

Bandopadhayay P, Jabbour AM, Riffkin C, Salmanidis M, Gordon L, Popovski D, Rigby L, Ashley DM, Watkins DN, Thomas DM, Algar E, Ekert PG.

BMC Cancer. 2013 Dec 9;13:585. doi: 10.1186/1471-2407-13-585.

28.

ER stress does not cause upregulation and activation of caspase-2 to initiate apoptosis.

Sandow JJ, Dorstyn L, O'Reilly LA, Tailler M, Kumar S, Strasser A, Ekert PG.

Cell Death Differ. 2014 Mar;21(3):475-80. doi: 10.1038/cdd.2013.168. Epub 2013 Nov 29.

29.

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.

Brumatti G, Salmanidis M, Kok CH, Bilardi RA, Sandow JJ, Silke N, Mason K, Visser J, Jabbour AM, Glaser SP, Okamoto T, Bouillet P, D'Andrea RJ, Ekert PG.

Oncotarget. 2013 Nov;4(11):1933-47.

30.

Seeking a MCL-1 inhibitor.

Brumatti G, Ekert PG.

Cell Death Differ. 2013 Nov;20(11):1440-1. doi: 10.1038/cdd.2013.114. No abstract available.

31.

Role of p53 in cAMP/PKA pathway mediated apoptosis.

Rahimi A, Lee YY, Abdella H, Doerflinger M, Gangoda L, Srivastava R, Xiao K, Ekert PG, Puthalakath H.

Apoptosis. 2013 Dec;18(12):1492-9. doi: 10.1007/s10495-013-0895-6.

PMID:
24002658
32.

BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis.

Wensveen FM, Geest CR, Libregts SFWM, Derks IAM, Ekert PG, Labi V, Villunger A, Nolte MA, Eldering E.

Apoptosis. 2013 Nov;18(11):1306-1318. doi: 10.1007/s10495-013-0890-y.

33.

Hoxb8 regulates expression of microRNAs to control cell death and differentiation.

Salmanidis M, Brumatti G, Narayan N, Green BD, van den Bergen JA, Sandow JJ, Bert AG, Silke N, Sladic R, Puthalakath H, Rohrbeck L, Okamoto T, Bouillet P, Herold MJ, Goodall GJ, Jabbour AM, Ekert PG.

Cell Death Differ. 2013 Oct;20(10):1370-80. doi: 10.1038/cdd.2013.92. Epub 2013 Jul 19.

34.

Akt1 is the principal Akt isoform regulating apoptosis in limiting cytokine concentrations.

Green BD, Jabbour AM, Sandow JJ, Riffkin CD, Masouras D, Daunt CP, Salmanidis M, Brumatti G, Hemmings BA, Guthridge MA, Pearson RB, Ekert PG.

Cell Death Differ. 2013 Oct;20(10):1341-9. doi: 10.1038/cdd.2013.63. Epub 2013 Jun 21.

35.

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA.

Blood. 2013 Aug 1;122(5):738-48. doi: 10.1182/blood-2012-08-447441. Epub 2013 Jun 17.

36.

Exploring the utility of human DNA methylation arrays for profiling mouse genomic DNA.

Wong NC, Ng J, Hall NE, Lunke S, Salmanidis M, Brumatti G, Ekert PG, Craig JM, Saffery R.

Genomics. 2013 Jul;102(1):38-46. doi: 10.1016/j.ygeno.2013.04.014. Epub 2013 Apr 29.

37.

In vitro differentiation of near-unlimited numbers of functional mouse basophils using conditional Hoxb8.

Gurzeler U, Rabachini T, Dahinden CA, Salmanidis M, Brumatti G, Ekert PG, Echeverry N, Bachmann D, Simon HU, Kaufmann T.

Allergy. 2013;68(5):604-13. doi: 10.1111/all.12140.

PMID:
23590216
38.

Signalling by the βc family of cytokines.

Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF.

Cytokine Growth Factor Rev. 2013 Jun;24(3):189-201. doi: 10.1016/j.cytogfr.2013.03.002. Epub 2013 Mar 25. Review.

PMID:
23535386
39.

Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.

Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA.

PLoS Biol. 2013;11(3):e1001515. doi: 10.1371/journal.pbio.1001515. Epub 2013 Mar 19.

40.

p53-Dependent transcriptional responses to interleukin-3 signaling.

Jabbour AM, Gordon L, Daunt CP, Green BD, Kok CH, D'Andrea R, Ekert PG.

PLoS One. 2012;7(2):e31428. doi: 10.1371/journal.pone.0031428. Epub 2012 Feb 14.

41.

The GM-CSF receptor family: mechanism of activation and implications for disease.

Hercus TR, Broughton SE, Ekert PG, Ramshaw HS, Perugini M, Grimbaldeston M, Woodcock JM, Thomas D, Pitson S, Hughes T, D'Andrea RJ, Parker MW, Lopez AF.

Growth Factors. 2012 Apr;30(2):63-75. doi: 10.3109/08977194.2011.649919. Epub 2012 Jan 18. Review.

PMID:
22257375
42.

Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death.

Sandow JJ, Jabbour AM, Condina MR, Daunt CP, Stomski FC, Green BD, Riffkin CD, Hoffmann P, Guthridge MA, Silke J, Lopez AF, Ekert PG.

Cell Death Differ. 2012 Apr;19(4):633-41. doi: 10.1038/cdd.2011.131. Epub 2011 Oct 14.

43.

Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D'Andrea RJ, Horwitz MS, Scott HS.

Nat Genet. 2011 Sep 4;43(10):1012-7. doi: 10.1038/ng.913.

44.

Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML.

Kok CH, Brown AL, Ekert PG, D'Andrea RJ.

Leukemia. 2010 Jun;24(6):1239-43. doi: 10.1038/leu.2010.85. Epub 2010 Apr 29. No abstract available.

PMID:
20428200
45.

Crossing paths: interactions between the cell death machinery and growth factor survival signals.

Brumatti G, Salmanidis M, Ekert PG.

Cell Mol Life Sci. 2010 May;67(10):1619-30. doi: 10.1007/s00018-010-0288-8. Epub 2010 Feb 16. Review.

PMID:
20157838
46.

Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes.

Oberle C, Huai J, Reinheckel T, Tacke M, Rassner M, Ekert PG, Buellesbach J, Borner C.

Cell Death Differ. 2010 Jul;17(7):1167-78. doi: 10.1038/cdd.2009.214. Epub 2010 Jan 22.

47.

Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation.

Jabbour AM, Daunt CP, Green BD, Vogel S, Gordon L, Lee RS, Silke N, Pearson RB, Vandenberg CJ, Kelly PN, Nutt SL, Strasser A, Borner C, Ekert PG.

Blood. 2010 Jan 14;115(2):344-52. doi: 10.1182/blood-2009-07-230730. Epub 2009 Nov 17.

48.

The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.

Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, Lopez AF.

Blood. 2009 Aug 13;114(7):1289-98. doi: 10.1182/blood-2008-12-164004. Epub 2009 May 12. Review.

49.

Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA, Ekert PG, Saffery R, Craig J, Johnstone RW, Ashley DM.

PLoS One. 2009;4(2):e4482. doi: 10.1371/journal.pone.0004482. Epub 2009 Feb 16.

50.

Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim.

Jabbour AM, Heraud JE, Daunt CP, Kaufmann T, Sandow J, O'Reilly LA, Callus BA, Lopez A, Strasser A, Vaux DL, Ekert PG.

Cell Death Differ. 2009 Apr;16(4):555-63. doi: 10.1038/cdd.2008.179. Epub 2008 Dec 12.

Supplemental Content

Loading ...
Support Center